Every milligram of dietary zinc that enters systemic circulation must first cross the basolateral membrane of an intestinal enterocyte. Only one protein manages that crossing at scale: ZnT1¹¹ ZnT1
Zinc Transporter 1, the product of SLC30A1 on chromosome 1q32.3; ubiquitously expressed, plasma-membrane localised, the dominant zinc efflux pump in most mammalian cell types. Without functional ZnT1, dietary zinc accumulates inside the enterocyte and never reaches the portal vein. The knockout phenotype in mice is lethal within weeks — a fact that underscores just how central this single protein is to whole-body zinc supply.

rs3738198 is an intronic variant (GRCh38 chromosome 1, position 211,576,392; G>C on the plus strand, C>G on the coding minus strand) lying within an intron of SLC30A1. The minor C allele (plus-strand) is present in roughly 13–15% of all chromosomes globally, with higher frequency in African (~22%) and East Asian (~20%) populations than in Europeans (~11%). No clinical significance entry exists in ClinVar, and no published study has directly tested this rsid in a phenotypic association study. Its biological plausibility rests on the gene's established, essential role in zinc homeostasis and the observation that SLC30A1 expression is exquisitely sensitive to regulatory inputs — making intronic regulatory variants a plausible source of inter-individual variability in zinc absorption efficiency.

The Mechanism

SLC30A1 encodes a homodimeric six-transmembrane-helix zinc transporter that coordinates zinc at two binding sites (Z1 and Z2) within the transmembrane core. Mutations at the Z2 site produce the most robust reductions in zinc export capacity, consistent with Z2 being the primary zinc-translocation interface²² Mutations at the Z2 site produce the most robust reductions in zinc export capacity, consistent with Z2 being the primary zinc-translocation interface. The protein is localised to the basolateral membrane of intestinal epithelial cells, the plasma and lysosomal membranes of macrophages, and the neuronal plasma membrane — wherever cells need to expel excess cytosolic zinc.

Gene expression is driven through two metal-response element (MRE) sequences in the SLC30A1 promoter. When intracellular zinc rises, the transcription factor MTF-1³³ MTF-1
Metal-regulatory transcription factor 1; the master zinc sensor that activates metallothionein and ZnT1 genes in response to cytosolic zinc elevation translocates to the nucleus and induces ZnT1 mRNA up to 12-fold within 3 hours. Conversely, dietary zinc deficiency down-regulates ZnT1 expression by ~40% to help cells retain zinc. An intronic variant like rs3738198 could influence this regulatory dynamic by altering splicing efficiency, intronic enhancer activity, or chromatin accessibility near MTF-1 binding sites — mechanisms that have not been specifically studied at this locus but are well-established for intronic variants at other transporter genes.

The Evidence

Gene essentiality: The most direct evidence for ZnT1's importance comes from mouse models. Ruaud et al. (2024)⁴⁴ Ruaud et al. (2024) showed that inducible intestinal-specific Slc30a1 knockout mice die within two weeks of gene deletion, with serum zinc crashing, intestinal barrier disruption, and massive inflammatory activation. Systemic zinc injection fully rescued all animals. This establishes intestinal SLC30A1 as the non-redundant gate for dietary zinc delivery.

Somatic mutations and ion selectivity: A 2023 Nature Genetics study by Nanba et al.⁵⁵ Nanba et al. identified recurrent in-frame deletions at the His43/Asp47 zinc-binding site in SLC30A1 as the driver of aldosterone-producing adenomas through gain-of-function sodium influx. While these are somatic coding mutations — distinct from the germline intronic rs3738198 — they demonstrate that even small structural changes near the zinc-binding site substantially alter ion transport selectivity, and that ZnT1 function is exquisitely sensitive to perturbation.

Immune zinc mobilisation: Stocks et al. (2021)⁶⁶ Stocks et al. (2021) showed that LPS-induced SLC30A1 in human macrophages delivers zinc into vesicular compartments around intracellular bacteria, creating a toxic zinc microenvironment that limits bacterial growth. This links ZnT1 not only to nutritional zinc supply but to the front line of innate immune defence.

Direct rs3738198 evidence: No published study has tested this specific intronic rsid for phenotypic association with serum zinc, immune function, or other outcomes. The evidence level for this variant specifically is accordingly emerging — biologically plausible, mechanistically grounded, but lacking direct human genetic evidence for phenotypic effect.

Practical Actions

Because rs3738198 is an intronic variant with no direct phenotypic evidence, practical guidance is drawn from the broader biology of ZnT1 and zinc homeostasis rather than from genotype-specific outcome data. The core idea is that anyone with a haplotype that may modestly reduce basolateral zinc export efficiency should ensure their dietary zinc supply is robust, use forms with higher bioavailability, and monitor for functional zinc inadequacy — recognising that the degree of risk from this specific variant alone is uncertain.

Zinc bioavailability from food varies dramatically: meat-source zinc (with animal proteins that enhance absorption) reaches 25–40% absorption efficiency, while phytate- rich plant sources (legumes, wholegrains) yield 10–15%. For someone whose intestinal ZnT1 may be at reduced capacity, optimising the bioavailability of dietary zinc provides a margin of safety without requiring supplementation.

Interactions

With SLC30A8 (ZnT8): SLC30A8 controls zinc secretion into insulin vesicles in pancreatic beta cells. While ZnT1 and ZnT8 operate in different tissues and contexts, their combined genetic load is relevant to understanding whole-body zinc distribution. Individuals carrying modestly reduced function in both a systemic zinc exporter (ZnT1/SLC30A1) and a tissue-specific zinc sequestrant (ZnT8/SLC30A8) may have atypical zinc partitioning between compartments.

With dietary zinc and phytate: The zinc-sensing MTF-1/ZnT1 axis is responsive to dietary zinc status. High-phytate diets that reduce zinc absorption will exacerbate any baseline reduction in ZnT1 export capacity, while zinc-adequate diets from high-bioavailability sources compensate. This gene-diet interaction is the primary lever available to C-allele carriers at this locus.

Calcium is the language of immune activation. When a T cell or B cell encounters its target antigen, a burst of intracellular calcium acts as the trigger for the immune response — switching on gene programs that drive proliferation, cytokine release, and antibody production. The ITPR3 gene encodes the inositol 1,4,5-trisphosphate receptor type 3¹¹ inositol 1,4,5-trisphosphate receptor type 3
IP3R3 is a calcium release channel on the endoplasmic reticulum membrane; it opens in response to IP3, a second messenger generated after immune receptor activation, one of the principal channels that mediates this calcium surge in lymphocytes. A common variant in the ITPR3 promoter — rs3748079 — quietly alters how much of this channel is produced, with consequences that ripple across several autoimmune conditions.

The Mechanism

The rs3748079 variant lies approximately 2 kilobases upstream of the ITPR3 transcription start site, squarely in the promoter region that controls how much ITPR3 protein a cell makes. The key functional difference between alleles is whether the transcription factor NKX2.5²² NKX2.5
NKX2.5 is a homeodomain transcription factor originally characterized in heart development but expressed in lymphocytes and other tissues can bind to this region. Oishi et al. demonstrated³³ Oishi et al. demonstrated
Electrophoretic mobility shift assay confirmed NKX2.5 protein binds specifically to the T allele sequence and not the C allele sequence at rs3748079 that NKX2.5 binds exclusively to the T allele sequence. The T allele creates a consensus NKX2.5 binding motif; the C allele disrupts it.

When NKX2.5 binds — which only happens in T allele carriers — it likely acts as a transcriptional repressor at this promoter site, dampening ITPR3 expression. Counterintuitively, this reduced channel expression appears protective against autoimmunity. C allele carriers (the majority) have unrestrained ITPR3 expression, which may amplify calcium signaling in lymphocytes and lower the threshold for immune activation. The net result is a background state of slightly heightened immune reactivity that predisposes to aberrant self-attacks.

ITPR3 sits within the MHC class III region⁴⁴ MHC class III region
The major histocompatibility complex on chromosome 6p21 contains three classes of genes: class I (antigen presentation), class II (T cell help), and class III (complement, cytokines, other immune genes). ITPR3 is a class III neighbor. of chromosome 6p21 — the immune gene-dense stretch that harbors HLA alleles and dozens of other autoimmune susceptibility loci. This proximity means rs3748079 associations must be carefully evaluated for linkage disequilibrium with neighboring MHC variants, though Lambertucci et al. found the ITPR3 contribution to type 1 diabetes was statistically distinct from MHC class II effects⁵⁵ statistically distinct from MHC class II effects
Regression analysis showed ITPR3 effect was independent of HLA-DR/DQ genotype in the Swedish T1D cohort.

The Evidence

The most comprehensive study comes from Oishi et al. 2008⁶⁶ Oishi et al. 2008
Case-control study of rs3748079 in two independent Japanese cohorts; total sample sizes not specified in abstract but p-values in the 10⁻⁸ range indicate thousands of subjects, who tested rs3748079 across three autoimmune diseases in Japanese populations. For SLE, the association was striking: odds ratio 1.88 (95% CI 1.51–2.35, p=1.78×10⁻⁸) for the risk genotype. Graves' disease showed OR 1.57 (95% CI 1.22–2.02), and rheumatoid arthritis OR 1.23 (95% CI 1.05–1.43). The replication across independent cohorts within the same study strengthens confidence in the associations.

The interaction finding is particularly notable: individuals carrying risk variants at both ITPR3 and NKX2.5 loci⁷⁷ NKX2.5 loci
NKX2.5 has independent genetic variants associated with SLE; the combined effect when both loci carry risk alleles reached OR=5.77, suggesting the two proteins act in the same pathway simultaneously showed a combined SLE odds ratio of 5.77 — far exceeding what either locus contributes alone. This gene-gene interaction confirms that the NKX2.5–ITPR3 transcriptional regulatory axis is a genuine biological pathway, not just a statistical artifact.

For type 1 diabetes, Lambertucci et al. 2006⁸⁸ Lambertucci et al. 2006
High-resolution 3 kb-interval SNP mapping across the ITPR3 locus in 1,124 Swedish subjects; most significant association at an intronic SNP (p=1.30×10⁻⁶) identified ITPR3 as a T1D susceptibility locus with recessive OR of 2.5 and an estimated population-attributable risk of 21.6% in Sweden — a substantial contribution from a single locus. The most associated variant in that study was intronic rather than rs3748079 specifically, but the overlapping disease profile across studies points to ITPR3's general role in autoimmune susceptibility.

An important limitation: most published work is in East Asian (Japanese) and Scandinavian populations. Independent replication in diverse ancestries is limited, and the ancestry-specific allele frequencies differ substantially (T allele at ~4% in Africans versus ~25–30% in South Asians). Effects in non-East Asian populations should be treated with greater caution.

Practical Actions

For CC genotype carriers (the majority), awareness of modestly elevated risk for SLE, Graves' disease, and RA is the main takeaway. These diseases share a pattern of chronic inflammation and autoantibody production. Early symptom recognition — joint pain, unexplained fatigue, skin rashes (especially butterfly rash for SLE), thyroid dysfunction signs, dry eyes or mouth — enables faster diagnosis. The association with type 1 diabetes (primarily identified in European populations) adds metabolic monitoring to the relevant domains.

Because ITPR3 regulates calcium signaling, environmental factors that modulate immune calcium flux — such as vitamin D status⁹⁹ vitamin D status
Vitamin D receptor signaling inhibits IP3-mediated calcium release in T cells, suggesting vitamin D sufficiency could modulate ITPR3-dependent immune activation; population data link low vitamin D to elevated SLE and RA risk and omega-3 fatty acid intake affecting membrane fluidity around calcium channels — may be particularly relevant to managing baseline immune tone in at-risk carriers. However, these connections are mechanistically plausible rather than directly proven for this specific variant.

Interactions

ITPR3 rs3748079 shows documented interaction with NKX2.5 variants. The combined risk (OR=5.77 for SLE) when both ITPR3 and NKX2.5 carry risk alleles is substantially greater than either alone, suggesting that NKX2.5 genetic variation modulates the functional consequence of the ITPR3 promoter variant. Since NKX2.5 is the transcription factor whose binding to the T allele confers protection, variants that reduce NKX2.5 expression or function would eliminate this protective effect even in T allele carriers.

The rs2229634 SNP in ITPR3 (a coding region variant) has been separately associated with Kawasaki disease complications and cervical cancer susceptibility in haplotype analysis with rs3748079. These SNPs may act in concert to regulate both ITPR3 expression and function, though the combined effects on autoimmune conditions have not been fully characterized.

ITPR3's location in the MHC class III region means its genetic effects should be interpreted in the context of an individual's full HLA profile. High-risk HLA haplotypes (HLA-DR3/4-DQ8 for T1D, HLA-DRB1 shared epitope for RA, HLA-DR2/3 for SLE) and ITPR3 risk alleles likely operate through distinct but converging mechanisms affecting immune tolerance.

The mineralocorticoid receptor¹¹ mineralocorticoid receptor
MR; the nuclear receptor for aldosterone and cortisol in the kidney sits at the heart of blood pressure regulation. When aldosterone binds MR in the distal nephron and collecting duct, the receptor translocates to the nucleus and upregulates the epithelial sodium channel (ENaC), driving sodium and water reabsorption. More sodium retained means a higher circulating volume and higher blood pressure. rs3910053 is an intronic variant within NR3C2 — the gene that encodes MR — that was identified in a controlled salt-loading study as a significant predictor of blood pressure elevation and long-term hypertension incidence.

The Mechanism

NR3C2 spans chromosome 4q31.1, a region rich in regulatory elements that control tissue-specific MR expression. rs3910053 sits approximately 11 kb deep in an intron, a position consistent with a regulatory role: intronic variants in nuclear receptor genes frequently fall within enhancer elements, splice-regulatory sequences, or binding sites for transcription factors that tune gene expression. The G allele at rs3910053 — the minor allele at ~25% global frequency — is the allele associated with elevated BP response to dietary sodium and with greater hypertension incidence over 14 years of follow-up. The most plausible mechanistic hypothesis is that the G allele increases MR expression or its aldosterone responsiveness in renal tubular cells, amplifying ENaC-mediated sodium reabsorption during high-salt conditions. This would explain the exaggerated blood pressure response to salt challenge seen in G carriers without requiring a change in the MR protein sequence.

The Evidence

The primary evidence for rs3910053 comes from Wang et al. 2025²² Wang et al. 2025
Associations of Genetic Variations in the NR3C2 With Salt Sensitivity, Longitudinal Blood Pressure Changes, and Incidence of Hypertension in Chinese Adults. J Clin Hypertens, 27(9):e70137, which studied 514 adults from 124 families in the GenSalt cohort through a controlled dietary sodium intervention (baseline → 3 g/day low-salt → 18 g/day high-salt phases) with 14 years of subsequent follow-up. rs3910053 showed significant negative correlations with systolic BP (SBP), diastolic BP (DBP), and mean arterial pressure (MAP) during the high-salt phase — meaning G allele carriers had greater blood pressure elevation under sodium loading — and was the NR3C2 variant most strongly associated with hypertension incidence across the follow-up period.

The broader NR3C2 locus has independent support. In the GenSalt replication dataset, He et al. 2015³³ He et al. 2015
Am J Hypertens 28:1310 found NR3C2 gene-based analysis significantly associated with longitudinal systolic BP change across 1,768 participants (P = 1×10⁻⁷), an association that replicated in Asian MESA participants (P = 1×10⁻⁴). Separately, the related NR3C2 variant rs5522 (I180V missense) has been shown to predict diastolic BP response to enalapril (Luo et al. 2014⁴⁴ Luo et al. 2014
Pharmacogenomics 15:201) and to associate with increased aldosterone levels and left ventricular hypertrophy in resistant hypertension (Ritter et al. 2016⁵⁵ Ritter et al. 2016
Am J Hypertens 29:245).

The limitation of the current evidence is that rs3910053's association derives from a single study in an East Asian cohort (n=514), without replication in independent cohorts or in non-Asian populations. The functional mechanism — how this intronic variant changes MR biology — has not been characterized. Evidence level is therefore emerging: single replication-grade study with a biologically coherent mechanism, but not yet replicated across independent populations.

Practical Actions

For carriers of one or two G alleles, the key intervention is dietary sodium control: the variant's effect is expressed specifically under high-salt conditions. Salt sensitivity means blood pressure rises more per gram of sodium consumed than in non-sensitive individuals, and research consistently shows that salt-sensitive individuals benefit more from sodium restriction than salt-resistant peers. Consistent monitoring of blood pressure — particularly during periods of higher sodium intake (travel, social events, restaurant meals) — provides early warning of MR-mediated volume expansion. For GG homozygotes, aldosterone-pathway medications (particularly MR antagonists such as spironolactone or eplerenone) are worth discussing with a physician if BP control is difficult, given the genetic evidence implicating MR overactivation.

Interactions

rs3910053 acts within the aldosterone–angiotensin axis alongside other blood pressure variants. The NR3C2 rs5522 I180V missense variant (in the ligand-binding domain) has been studied more extensively for drug response and cardiac outcomes — carriers of both rs3910053 G and rs5522 G are likely to have compounded MR-axis activation. The ENaC genes SCNN1B and SCNN1G (the downstream effectors of MR signaling) also carry common variants associated with BP in the same Tobin 2008 family study that found NR3C2 associations. Pathway interactions with ACE/ACE2, AGT, and AGTR1 variants are biologically expected in the salt-sensitivity phenotype and may compound the effect of rs3910053 on hypertension risk.

KLKB1¹¹ KLKB1
Kallikrein B1 — encodes plasma prekallikrein (Fletcher factor), a serine protease that circulates in blood as an inactive zymogen complexed with high-molecular-weight kininogen (HK) is the central enzyme of the plasma contact activation pathway. When factor XII (Hageman factor)²² factor XII (Hageman factor)
the initiating serine protease of the intrinsic coagulation cascade, activated by contact with negatively charged surfaces is activated, it converts plasma prekallikrein into plasma kallikrein — an active protease with far-reaching effects on coagulation, inflammation, blood pressure, and vascular tone. The rs4253238 intronic variant in KLKB1 modulates how much plasma kallikrein activity the liver produces, with downstream consequences for bradykinin generation, endothelin regulation, and thrombotic risk.

The Mechanism

rs4253238 sits in an intron of KLKB1 on chromosome 4q35.2. Although it does not change the plasma prekallikrein protein sequence, research by Sidarovich and Fink³³ Sidarovich and Fink
Sidarovich V, Fink E. The 3'-terminal 13-bp segment of intron 1 is sufficient to promote transcriptional activity in the KLKB1 gene. Gene, 2009 demonstrated that the KLKB1 intron 1 harbors a 13-bp regulatory element sufficient to promote transcriptional activity and recruit alternative promoters. Intronic variants in this regulatory region plausibly alter the level of KLKB1 mRNA produced in the liver and kidney, where the gene is predominantly expressed. The T allele at rs4253238 is associated with increased plasma kallikrein enzymatic activity.

Active plasma kallikrein has multiple substrates. Its classical function is to cleave high-molecular-weight kininogen⁴⁴ high-molecular-weight kininogen
the plasma protein that serves as the precursor to bradykinin, the vasodilatory, pro-inflammatory peptide central to ACE-inhibitor activity to release bradykinin. Beyond bradykinin, plasma kallikrein also cleaves precursors of endothelin-1 (ET-1) and adrenomedullin (ADM)⁵⁵ endothelin-1 (ET-1) and adrenomedullin (ADM)
ET-1 is a potent vasoconstrictor and predictor of cardiac death; ADM is a vasodilatory peptide elevated in heart failure into smaller peptide fragments. The measurement of CT-pro-endothelin-1 and MR-pro-adrenomedullin as circulating surrogates of ET-1 and ADM activity means that higher plasma kallikrein activity registers as elevated levels of these cardiovascular biomarkers.

The Evidence

The primary cardiovascular evidence comes from a large genome-wide association study of plasma CT-proET-1 and MR-proADM⁶⁶ genome-wide association study of plasma CT-proET-1 and MR-proADM
Verweij N et al. Genome-wide association study on plasma levels of midregional-proadrenomedullin and C-terminal-pro-endothelin-1. Hypertension, 2013 conducted in 3,444 discovery participants with replication in 3,230 additional European participants. Minor variants in KLKB1, including rs4253238, showed genome-wide significant associations with both MR-proADM (P=4.46×10⁻⁵²) and CT-proET-1 (P=1.23×10⁻¹²²). The researchers demonstrated mechanistically that purified plasma kallikrein can directly cleave both ADM and ET-1 precursor proteins into multiple smaller peptides, providing a biochemical explanation for the genetic association. Elevated CT-proET-1 and MR-proADM are established predictors of cardiac death and heart failure.

An independent genome-wide protein QTL study⁷⁷ genome-wide protein QTL study
Portelli MA et al. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J, 2014 in 584 control/asthma participants and 219 COPD participants confirmed that the rs4253238 T:T genotype is directly associated with elevated plasma kallikrein enzymatic activity (combined P=5.04×10⁻¹²). Higher kallikrein activity was inversely correlated with circulating soluble uPAR levels, a receptor involved in vascular repair and inflammatory signaling.

The cardiovascular implications of altered plasma kallikrein activity were clarified by Stavrou et al.⁸⁸ Stavrou et al.
Stavrou EX et al. Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood, 2015 who found that Klkb1-knockout mice show significantly delayed arterial thrombosis — the paradoxical protection arising from upregulation of the Mas receptor/prostacyclin axis and suppression of tissue factor. This study establishes plasma kallikrein as a net pro-thrombotic driver in the contact activation pathway; higher KLKB1 activity from the T allele thus associates with a modestly more pro-thrombotic vascular environment.

A review by Feener et al.⁹⁹ Feener et al.
Feener EP et al. Role of plasma kallikrein in diabetes and metabolism. Thromb Haemost, 2013 confirmed that common KLKB1 variants associate with blood metabolite levels, hypertension, and coagulation in population studies. Notably, the Rohmann 2019¹⁰¹⁰ Rohmann 2019
Rohmann JL et al. Genetic determinants of activity and antigen levels of contact system factors. J Thromb Haemost, 2019 GWAS found that contact activation variants were not significantly associated with myocardial infarction or stroke risk in women under 50, suggesting that the kallikrein-modulating effect of rs4253238 primarily manifests as altered biomarker levels rather than directly elevated event risk in isolation.

Practical Implications

The T allele elevates plasma kallikrein activity, which simultaneously elevates bradykinin (vasodilatory, cardioprotective) and increases cleavage of ET-1 precursors (elevating circulating CT-proET-1, a cardiac stress marker). The net clinical significance of this variant is not fully resolved — elevated bradykinin is protective in ischemic conditioning and may enhance ACE-inhibitor effects, while elevated CT-proET-1 signals greater endothelin pathway activity associated with cardiac load. Heterozygotes (CT) have intermediate kallikrein activity levels. Monitoring cardiovascular biomarkers (particularly high-sensitivity CRP, BNP/NT-proBNP, and if available CT-proET-1) provides the most actionable information for TT genotype carriers.

Interactions

rs4253238 (KLKB1) has a documented epistatic interaction with rs2731672 (F12, coagulation factor XII), the upstream activating protease in the contact system. Together, KLKB1 and F12 variants modulate the full throughput of the contact activation cascade — bradykinin generation, complement activation, and endothelin surrogate levels. The Verweij 2013 GWAS identified both rs4253238 (KLKB1) and rs2731672 (F12) as independent contributors to CT-proET-1 and MR-proADM plasma levels, consistent with additive effects along the same proteolytic axis. The Gianni 2017 study (PMID 29130992) also demonstrated that combined KLKB1-428 and F12-46C/T variants produce an 8.8-year delay in hereditary angioedema onset — confirming meaningful gene-gene epistasis between these two contact system proteins. Carriers of risk genotypes in both rs4253238 (KLKB1) and rs2731672 (F12) likely have the highest contact-activation throughput and greatest endothelin/adrenomedullin surrogate elevation.

The UMOD gene encodes uromodulin¹¹ uromodulin
Also called Tamm-Horsfall protein, uromodulin is the most abundant protein in normal human urine, produced exclusively by cells lining the thick ascending limb of the loop of Henle, a protein with a paradoxical dual role in kidney health. Uromodulin forms protective filaments in urine that trap bacteria and prevent urinary tract infections²² trap bacteria and prevent urinary tract infections
Uromodulin polymerizes into filaments that bind type 1 fimbriae on uropathogenic E. coli, blocking their attachment to the bladder wall, but it also activates sodium reabsorption in the kidney, driving up blood pressure. The rs4293393 variant sits in the UMOD promoter region³³ UMOD promoter region
Located 550 base pairs upstream of the transcription start site, within a glucocorticoid response element, where it controls how much uromodulin your kidneys produce — and more is not always better.

The Mechanism

The rs4293393 risk allele (A on the plus strand, reported as T in the medical literature since UMOD is on the minus strand) sits within a glucocorticoid response element⁴⁴ glucocorticoid response element
A DNA sequence where glucocorticoid receptor proteins bind to regulate gene transcription in the UMOD promoter. The risk allele approximately doubles promoter activity⁵⁵ doubles promoter activity
Luciferase reporter assays showed ~2-fold higher transcription with the risk allele across multiple kidney cell lines compared to the protective G allele, leading to higher uromodulin production. This excess uromodulin activates the NKCC2 sodium-potassium-chloride cotransporter⁶⁶ NKCC2 sodium-potassium-chloride cotransporter
The key sodium reabsorption channel in the thick ascending limb of the loop of Henle, activated via SPAK/OSR1 kinase signaling in the thick ascending limb of the loop of Henle, increasing sodium reabsorption and driving salt-sensitive hypertension. The same mechanism causes progressive kidney damage through sustained hemodynamic stress on nephrons.

The Evidence

The UMOD promoter locus is one of the strongest and most replicated GWAS signals for kidney function. A landmark Icelandic study⁷⁷ landmark Icelandic study
Gudbjartsson et al. PLoS Genetics 2010 — 3,203 CKD cases and 38,782 controls from deCODE found the risk allele conferred CKD susceptibility with OR 1.25 (P = 4.1 x 10⁻¹⁰), while paradoxically protecting against kidney stones (OR 0.88, P = 5.7 x 10⁻⁵). A critical finding was that the effect on serum creatinine is strongly age-dependent⁸⁸ strongly age-dependent
Negligible before age 50 but accelerating rapidly after, at ~0.09 μmol/L per allele per year — negligible before age 50 but increasing sharply thereafter, particularly in the presence of comorbidities like diabetes and hypertension.

The Framingham Heart Study⁹⁹ Framingham Heart Study
Köttgen et al. JASN 2010 — 200 FHS participants with uromodulin measurements and genotyping demonstrated a striking dose-response: urinary uromodulin concentrations were 5.5 μg/mL with two risk alleles versus just 1.5 μg/mL with two protective alleles, and elevated uromodulin preceded incident CKD (OR 1.72 per SD increase).

The largest study to date, a PheWAS in 648,593 veterans¹⁰¹⁰ PheWAS in 648,593 veterans
Hung et al. Kidney Int Rep 2022 — Million Veteran Program multiethnic biobank from the Million Veteran Program, confirmed CKD risk (OR 1.22), hypertension (OR 1.03), gout (OR 1.04), and demonstrated protective effects against UTIs (OR 0.94) and kidney stones (OR 0.85) — all in non-Hispanic White participants. Notably, these associations were absent or attenuated in Black participants.

Practical Implications

The UMOD risk allele is extraordinarily common — carried by approximately 80% of people of European and African ancestry and over 90% in East Asian populations. This high frequency is maintained by pathogen-driven natural selection¹¹¹¹ pathogen-driven natural selection
Olden et al. JASN 2016 — analysis of 156 worldwide populations showed UMOD risk allele frequency correlates with bacterial diversity and UTI-causing pathogen prevalence: the same allele that increases CKD risk also protects against urinary tract infections, a major cause of morbidity throughout human evolution. The protective allele was found in Neanderthal and Denisovan genomes but has been selected against in modern humans, likely because UTI protection was more immediately advantageous than avoiding late-onset kidney disease.

The strongly age-dependent effect means this variant matters most after age 50, especially in the context of other metabolic risk factors. The mechanism through NKCC2 activation makes this a genuinely salt-sensitive form of hypertension — carriers may respond specifically to loop diuretics¹²¹² loop diuretics
Studies showed the loop diuretic furosemide produced greater blood pressure reduction and natriuresis in homozygous risk carriers compared to non-carriers and sodium restriction.

Interactions

rs4293393 is in near-perfect linkage disequilibrium¹³¹³ near-perfect linkage disequilibrium
r² = 0.95–1.0 in HapMap CEU populations with rs12917707, meaning these two SNPs are effectively the same signal — a person's genotype at one nearly always predicts their genotype at the other. Both tag the same UMOD promoter haplotype. rs13333226 is another SNP in the same LD block with concordant effects on uromodulin expression and CKD risk.

The UMOD mechanism intersects with other kidney function pathways. Variants in SLC22A2 (organic cation transporter, relevant to metformin clearance), SLC34A1 (phosphate transport), and APOL1 (African-ancestry CKD risk) affect kidney function through independent mechanisms and could compound CKD risk when present alongside the UMOD risk allele.

Your genome is copied and transmitted to the next generation in sperm and eggs. Every round of cell division during gametogenesis introduces errors — and the mismatch repair (MMR) system¹¹ mismatch repair (MMR) system
the cellular machinery that corrects base mismatches and insertion/deletion errors after DNA replication catches most of them before they become permanent. MSH2 is the central scaffold of this system: it forms the MutSα heterodimer with MSH6 to detect mismatches, and the MutSβ heterodimer with MSH3 to handle larger insertion/deletion loops. The Gly322Asp variant sits in the connector domain of MSH2, a structural region that mediates the critical handoff between mismatch recognition and downstream repair signaling through MLH1.

The Mechanism

Glycine at position 322 is part of a conserved loop in MSH2's connector domain (domain II), which serves as the physical interface with MutL homologs²² MutL homologs
the MLH1-PMS2 complex that executes strand excision after mismatch recognition. Replacing glycine — a structurally flexible amino acid — with aspartate introduces a bulkier, charged side chain that subtly alters connector domain geometry. Functional studies give mixed results: an in vitro MMR assay using human nuclear extracts found statistically significant reduction in repair efficiency (~10% of wild-type³³ statistically significant reduction in repair efficiency (~10% of wild-type
Andres et al. 2014, PMC4273566), while an earlier study using purified recombinant protein found no impairment in MSH2-MSH6 complex formation, mismatch binding, or repair activity (Kariola et al. 2008)⁴⁴ (Kariola et al. 2008). The discrepancy likely reflects assay sensitivity: purification steps may exclude structurally damaged heterodimers, making cell extract assays more representative of in vivo conditions.

The Evidence

The most definitive evidence comes from a genome-scale study in Iceland. Kristmundsdottir et al. (2023, Nature Communications)⁵⁵ Kristmundsdottir et al. (2023, Nature Communications)
Sequence variants affecting the genome-wide rate of germline microsatellite mutations analyzed whole-genome sequences from 6,084 Icelandic parent-offspring trios and identified rs4987188[A] as a variant that significantly increases transmitted microsatellite de novo mutations: +13.1 mutations in the paternal lineage and +7.8 in the maternal lineage per offspring per generation (P = 3.6×10⁻¹⁰, effect size 0.37 standard deviations). At a baseline of ~64 microsatellite de novo mutations per generation, the A allele represents a ~12–20% increase in germline microsatellite instability, carried symmetrically through both sperm and eggs. Crucially, the similar effect in both sexes indicates that germ cells from both parents are subject to the same MSH2-dependent sequence fidelity process.

ClinVar classification is Benign for Lynch syndrome (expert panel reviewed, InSiGHT September 2013, VCV000001762), based on allele frequency exceeding 1% in the population, lack of disease segregation in Lynch families, and the absence of clear mismatch repair deficiency on standard assays. The germline mutation-rate effect is a distinct phenotype from Lynch syndrome: it does not cause microsatellite instability in tumor DNA, but does modestly increase the per-generation mutation load passed to children.

Smaller case-control studies have explored cancer associations with inconsistent results. A Polish series found MSH2 Gly322Asp associated with colorectal cancer recurrence (p=0.001)⁶⁶ MSH2 Gly322Asp associated with colorectal cancer recurrence (p=0.001)
Plawski et al. 2017 and a separate Polish cohort reported a protective association with triple-negative breast cancer for the Asp allele, though these studies are small (n ≈ 70–144) and have not been replicated in larger populations.

Practical Actions

For AG heterozygotes, the effect on germline mutation rate is modest — a ~10–15% above-baseline increase in transmitted microsatellite mutations. No specific medical intervention is currently indicated. The finding is most relevant for genetic counseling context in families with unexplained de novo diseases or autism spectrum conditions (where microsatellite instability is one contributor to de novo mutation burden), and for couples undergoing IVF where preimplantation genetic testing for aneuploidy (PGT-A) is already planned.

For AA homozygotes (extremely rare, <0.03% globally), the expected additive effect would be roughly double the heterozygote increase in germline mutation rate. Given how rarely this genotype occurs, robust clinical data specific to AA homozygosity are unavailable; the recommendations remain an extrapolation from the per-allele dosage effect.

Interactions

MSH2 works in obligate heterodimer complexes, so the biological output of Gly322Asp depends on the functional state of its partners — particularly MSH6 (rs2303426 in the MSH2-MSH6 interface region) and MLH1 (rs1799977, already in the GeneOps database). The variant in MLH1 (rs1799977, Ile219Val) sits in the MLH1 ATPase domain that docks with MSH2's connector domain; if a person carries both rs4987188 (MSH2 G322D) and rs1799977 (MLH1 I219V), the connector-domain interface is disrupted from both ends. A compound action covering this combination is worth investigating if familial MMR deficiency studies show additive effects.

EXO1 (rs72755295 and rs1635501 in the GeneOps database) acts downstream of MSH2 in the excision step; MSH2-EXO1 pathway efficiency is relevant to meiotic crossover fidelity. Variants in EXO1 combined with MSH2 G322D could compound the germline mutation-rate phenotype through reduced excision capacity after mismatch recognition.

LRP8, also known as ApoER2 (apolipoprotein E receptor 2), is the only member of the low-density lipoprotein receptor family expressed in platelets. It plays a central role in platelet activation, lipoprotein metabolism¹¹ lipoprotein metabolism
LRP8 binds apolipoprotein E-containing lipoproteins and modulates their clearance from the bloodstream, and inflammatory signaling in macrophages and endothelial cells. The rs5177 variant sits in the 3' untranslated region of LRP8 and has been studied primarily as part of a haplotype block flanking the functional R952Q coding variant — together forming the TACGC haplotype²² TACGC haplotype
a five-SNP haplotype (rs7546246, rs2297660, rs3737983, R952Q/rs5174, rs5177) found exclusively in patients with familial and early-onset coronary artery disease and myocardial infarction.

The C allele at rs5177 marks one end of this risk haplotype in white populations and is notably absent from most African-ancestry populations (~1% frequency), while reaching moderate frequencies in Europeans (~32%) and high frequencies in East Asian populations (~46%), though the haplotype association with CAD has not been established in East Asian cohorts.

The Mechanism

rs5177 is a 3'UTR variant³³ 3'UTR variant
variants in the 3' untranslated region regulate mRNA stability, translation efficiency, and miRNA binding sites, altering how much protein is ultimately produced from the gene. Studies in psychiatric genetics examining LRP8 expression found that rs5177 is an expression quantitative trait locus (eQTL)⁴⁴ expression quantitative trait locus (eQTL)
the allele at this position predicts LRP8 mRNA levels in brain and other tissues, confirming it has a real functional effect on LRP8 expression rather than being a purely neutral tag.

The cardiovascular relevance of LRP8 expression changes arises from the protein's role in platelets — LRP8 is the only LRP family member expressed on platelets⁵⁵ LRP8 is the only LRP family member expressed on platelets
where it modulates HDL-mediated inhibition of platelet activation via apolipoprotein E signaling. Increased LRP8 expression has been associated with enhanced platelet reactivity and thrombotic risk. The R952Q coding variant (rs5174)⁶⁶ R952Q coding variant (rs5174)
a glutamine substitution at position 952 of the LRP8 cytoplasmic tail in tight haplotype linkage with rs5177 further increases p38 MAPK activation by oxidized LDL, amplifying the platelet and inflammatory response to atherogenic lipoproteins.

Additionally, LRP8-deficient mouse models⁷⁷ LRP8-deficient mouse models
animals lacking functional ApoER2 develop aortic dissection under angiotensin II infusion through dysregulated macrophage activity, suggesting LRP8 expression level in myeloid cells affects vascular wall integrity under hypertensive stress.

The Evidence

The strongest evidence comes from a series of studies by Shen, Wang, and colleagues using the GeneQuest family cohort of patients with premature coronary artery disease and MI. The 2007 discovery paper⁸⁸ 2007 discovery paper
Shen GQ et al., American Journal of Human Genetics 2007;81(4):780-91 identified the LRP8 locus through genome-wide linkage analysis of 428 families with premature MI, then fine-mapped to the R952Q variant. By 2014, haplotype analysis including rs5177⁹⁹ haplotype analysis including rs5177
Shen GQ et al., Circulation Cardiovascular Genetics 2014;7(4):514-20 showed the TACGC risk haplotype was present only in CAD/MI patients and absent from healthy controls, achieving genome-wide significance of P=7.4×10⁻⁷ for CAD and P=2.2×10⁻⁹ for MI¹⁰¹⁰ genome-wide significance of P=7.4×10⁻⁷ for CAD and P=2.2×10⁻⁹ for MI
in the GeneQuest cohort of 381 premature CAD cases vs. 560 controls, with replication in an Italian cohort of 248 familial MI patients (P=0.041). Notably, TACGC homozygotes showed earlier disease onset and higher LDL cholesterol levels¹¹¹¹ earlier disease onset and higher LDL cholesterol levels
compared to heterozygotes, indicating a dose-response relationship.

Complementary 2013 haplotype work¹²¹² 2013 haplotype work
Shen GQ et al., Gene 2013;521(1):78-81 identified a protective TCCGC haplotype (rs5177 G allele) with OR 0.53 for CAD (P=4.0×10⁻¹¹) and OR 0.42 for MI (P=6.5×10⁻¹²)¹³¹³ OR 0.53 for CAD (P=4.0×10⁻¹¹) and OR 0.42 for MI (P=6.5×10⁻¹²)
in the GeneQuest cohort, replicated in Italy with OR 0.71 (P=0.004), reinforcing that the G allele at rs5177 tags the protective haplotype.

Critically, a large null replication¹⁴¹⁴ large null replication
Lieb W et al., Journal of Molecular Medicine 2008;86(10):1163-70 examined LRP8 variants across four German and British cohorts totaling over 6,700 participants and found no significant association between LRP8 variants (including the rs5177 proxy rs5174) and familial or sporadic MI. This limits evidence confidence — the association appears strongest in selected familial early-onset cohorts and was absent in the South Korean replication population, suggesting population- or family-history-specific enrichment.

Practical Implications

The C allele at rs5177 tags the LRP8 risk haplotype in individuals of European ancestry with a family history of premature heart disease. The effect is most meaningful in the context of familial cardiovascular disease — where it may represent a heritable molecular marker — rather than as a general population risk predictor. The evidence supports heightened attention to platelet function, lipid management, and inflammatory markers in C allele carriers with relevant family history.

Monitoring LDL cholesterol levels is particularly important: the TACGC haplotype is associated with elevated plasma LDL and triglycerides¹⁵¹⁵ elevated plasma LDL and triglycerides
particularly in patients with early-onset CAD, suggesting lipid optimization should be a primary intervention target. Given LRP8's role in platelet activation, antiplatelet strategies may be especially relevant for affected individuals.

Interactions

The rs5177 C allele exists in tight haplotype linkage with the functional R952Q coding variant (rs5174)¹⁶¹⁶ R952Q coding variant (rs5174)
a missense change in the LRP8 cytoplasmic tail that increases p38 MAPK activation by oxidized LDL and enhances platelet reactivity. The combined TACGC haplotype (spanning rs7546246, rs2297660, rs3737983, rs5174, and rs5177) represents a coherent risk unit in white populations — the individual SNPs have limited power alone but together define a molecular diagnostic marker for familial premature CAD. When rs5177 C is present alongside rs5174 Q (risk) allele, the combined haplotype effect is stronger than either variant alone.

Your liver cells constantly remodel the fatty acid tails of membrane phospholipids, swapping in and out different acyl chains to maintain proper membrane composition and signaling. The MBOAT7 gene¹¹ MBOAT7 gene
membrane-bound O-acyltransferase domain-containing 7, also known as LPIAT1 (lysophosphatidylinositol acyltransferase 1) encodes the enzyme responsible for one specific and critical step in this process: re-acylating lysophosphatidylinositol (lyso-PI)²² lysophosphatidylinositol (lyso-PI)
a phospholipid stripped of its sn-2 fatty acid tail with arachidonoyl-CoA to produce PI(18:0/20:4), the dominant phosphatidylinositol species in hepatocyte membranes. The rs641738 variant reduces MBOAT7 expression in the liver, depleting this key phospholipid and tipping the balance toward hepatic fat accumulation and inflammation.

The Mechanism

MBOAT7 operates within the Lands cycle³³ Lands cycle
a phospholipid remodeling pathway where phospholipase A2 cleaves the sn-2 fatty acid from a phospholipid, creating a lysophospholipid, and an acyltransferase re-esterifies it with a new fatty acid. What makes MBOAT7 unique among the MBOAT family is its exquisite substrate selectivity: it preferentially esterifies arachidonoyl-CoA (C20:4, an omega-6 fatty acid) into the sn-2 position of lyso-PI. This selectivity means MBOAT7 is the primary enzyme determining how much arachidonic acid ends up in phosphatidylinositol pools.

The rs641738 T allele sits in the regulatory region between MBOAT7 and TMC4 on chromosome 19. It does not change the MBOAT7 protein sequence, but it reduces MBOAT7 mRNA and protein expression in hepatocytes. Lipidomic profiling of human liver biopsies shows that T allele carriers have markedly reduced PI species containing arachidonoyl chains — primarily PI(18:0/20:4) — and elevated levels of the precursor 18:0-lyso-PI and 18:1-lyso-PI⁴⁴ Lipidomic profiling of human liver biopsies shows that T allele carriers have markedly reduced PI species containing arachidonoyl chains — primarily PI(18:0/20:4) — and elevated levels of the precursor 18:0-lyso-PI and 18:1-lyso-PI
Luukkonen et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol, 2016. The functional consequence is a deficit in arachidonoyl-PI, which disrupts membrane signaling, lipid droplet dynamics, and inflammatory tone in the liver.

When MBOAT7 activity falls, the accumulation of lyso-PI and the depletion of mature PI species promote de novo lipogenesis and triglyceride accumulation in hepatocytes. MBOAT7 also appears to shape the availability of arachidonic acid for downstream eicosanoid production, linking phospholipid remodeling to inflammatory signaling in Kupffer cells and hepatic stellate cells.

The Evidence

The variant was first identified as a NAFLD risk locus in the landmark study by Mancina et al.⁵⁵ landmark study by Mancina et al.
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, which examined 3,854 participants in the multi-ethnic Dallas Heart Study and 1,149 European liver biopsy patients. Each T allele increased risk of hepatic steatosis (OR 1.42 in the biopsy cohort), NASH (OR 1.18), and significant fibrosis (OR 1.30). In European Americans specifically, the per-allele OR for steatosis was 1.37.

The definitive evidence came from a meta-analysis of 42 studies encompassing over one million participants (9,688 with liver biopsies)⁶⁶ meta-analysis of 42 studies encompassing over one million participants (9,688 with liver biopsies)
Teo et al. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. J Hepatol, 2021. This analysis confirmed that the T allele increases risk of NAFLD diagnosis (OR 1.17), advanced fibrosis under a recessive model (OR 1.22), and elevated ALT, while lowering serum triglycerides. Crucially, the association was robust in European adults but was not replicated in children or in non-European populations, suggesting the effect may be modulated by environmental or developmental factors.

Beyond NAFLD, rs641738 T increases risk of liver inflammation and accelerated fibrosis progression in chronic hepatitis C⁷⁷ rs641738 T increases risk of liver inflammation and accelerated fibrosis progression in chronic hepatitis C
Thabet et al. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat Commun, 2016 (n=2,051), and increases hepatocellular carcinoma risk in non-cirrhotic patients with liver disease⁸⁸ increases hepatocellular carcinoma risk in non-cirrhotic patients with liver disease
Donati et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep, 2017 (OR 2.10 in combined non-cirrhotic cohort).

The effect size of rs641738 is modest compared to PNPLA3 rs738409 (the strongest NAFLD risk variant), but it acts through an independent pathway — phospholipid remodeling rather than triglyceride hydrolysis — making it a complementary risk factor with additive effects when combined with PNPLA3 and TM6SF2 risk alleles.

Practical Actions

For T allele carriers, the key insight is that your liver's phosphatidylinositol remodeling is compromised. MBOAT7 preferentially incorporates arachidonic acid (an omega-6 PUFA) into PI, and when this process is impaired, the ratio of omega-6 to omega-3 fatty acids in hepatic membranes shifts. Dietary strategies that increase EPA and DHA intake can partially compensate by providing alternative substrates for membrane phospholipid composition and by dampening the inflammatory signaling that MBOAT7 deficiency amplifies.

Monitoring liver enzymes (ALT, GGT) is particularly relevant because the T allele independently raises ALT. A mildly elevated ALT in a TT homozygote may reflect the genetic predisposition rather than acute liver injury, but it also signals that the liver is under more metabolic stress than the same ALT value would indicate in a CC individual.

Interactions

MBOAT7 rs641738 interacts additively with PNPLA3 rs738409 and TM6SF2 rs58542926. In a multicenter biopsy-based study of 515 NAFLD patients⁹⁹ multicenter biopsy-based study of 515 NAFLD patients
Krawczyk et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity. J Lipid Res, 2017, the three variants contributed through distinct mechanisms: PNPLA3 drove both steatosis and fibrosis, TM6SF2 primarily steatosis, and MBOAT7 selectively fibrosis (OR 1.77 in multivariate analysis). Increasing numbers of risk alleles across all three loci correlated with progressively higher liver enzymes.

The MTARC1 protective variant (rs2642438) operates in a complementary pathway — while MBOAT7 deficiency impairs phospholipid remodeling, MTARC1 loss-of-function enhances hepatic fat oxidation. Carriers of MBOAT7 risk alleles who also carry MTARC1 protective alleles may experience partial offset of their fibrosis risk, though this specific interaction has not yet been directly quantified.

HSD17B13 rs72613567 (a protective splice variant) also interacts with MBOAT7 risk through complementary mechanisms: HSD17B13 loss-of-function reduces hepatic lipid droplet toxicity while MBOAT7 deficiency increases it, making the presence or absence of HSD17B13 protection relevant for MBOAT7 risk carriers.

Chromosome 8q24 is the most frequently implicated region in cancer genome-wide association studies, yet it contains no protein-coding genes for hundreds of kilobases. The variant rs6983267 sits in an intergenic desert roughly 335 kilobases upstream of MYC¹¹ MYC
MYC is one of the most potent human oncogenes; its protein product drives cell proliferation, and it is overexpressed in the majority of human cancers, one of the most important oncogenes in human biology. Despite its distance from any gene, this single nucleotide change has a direct and well-characterized mechanism linking it to cancer risk.

The Mechanism

The region surrounding rs6983267 functions as a transcriptional enhancer — a stretch of DNA that boosts the expression of distant genes through physical looping of the chromosome. Pomerantz et al.²² Pomerantz et al.
Pomerantz MM et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet, 2009 used chromosome conformation capture (3C) to demonstrate that this enhancer physically contacts the MYC promoter across 335 kb of intervening DNA. The G risk allele creates a stronger binding site for TCF7L2³³ TCF7L2
Also known as TCF4; a transcription factor in the Wnt signaling pathway that, when activated, drives expression of growth-promoting genes including MYC, a key transcription factor in the Wnt signaling pathway⁴⁴ Wnt signaling pathway
The Wnt pathway controls cell proliferation, polarity, and fate during development; its aberrant activation is a hallmark of colorectal cancer.

Tuupanen et al.⁵⁵ Tuupanen et al.
Tuupanen S et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet, 2009 confirmed this mechanism using reporter assays and chromatin immunoprecipitation: the G allele binds TCF7L2 more strongly both in vitro and in vivo, effectively amplifying Wnt-driven MYC expression. In the most striking functional validation, Sur et al.⁶⁶ Sur et al.
Sur IK et al. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science, 2012 deleted this enhancer region in mice and found they were markedly resistant to intestinal tumors driven by APC mutations — the same pathway responsible for most human colorectal cancers.

The Evidence

rs6983267 is one of the most replicated cancer GWAS findings in the literature. The initial identification came from two independent 2007 studies: Tomlinson et al.⁷⁷ Tomlinson et al.
Tomlinson I et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet, 2007 found the G allele increased colorectal cancer risk with an OR of 1.27 for heterozygotes and 1.47 for GG homozygotes in a large British cohort. Simultaneously, Haiman et al.⁸⁸ Haiman et al.
Haiman CA et al. A common genetic risk factor for colorectal and prostate cancer. Nat Genet, 2007 showed the same variant conferred risk for both colorectal and prostate cancer with an OR of 1.22 per allele.

A comprehensive meta-analysis of 78 studies⁹⁹ comprehensive meta-analysis of 78 studies
Zhu M et al. Association between 8q24 rs6983267 polymorphism and cancer susceptibility: a meta-analysis involving 170,737 subjects. Oncotarget, 2017 pooling 73,996 cancer cases and 96,741 controls confirmed statistically robust associations across multiple cancer types. The GG genotype conferred an OR of 1.31 compared to TT, while per-allele risk was 1.14. The association was strongest for colorectal cancer in Caucasians and prostate cancer in both Caucasians and Asians.

A critical point: this is a very common variant with a small per-allele effect. The G allele is actually the major allele in most populations (frequency ~50-58%), meaning the majority of people carry at least one copy. The absolute risk increase per individual is modest — this is not a rare, high-penetrance mutation like BRCA1. Its public health significance comes from its extreme prevalence.

Practical Implications

The actionability of rs6983267 centers on cancer screening adherence rather than lifestyle interventions. Because the Wnt/MYC mechanism directly promotes colorectal neoplasia through adenoma formation, colonoscopy screening is the most evidence-based response — it detects and removes the precancerous adenomas that this variant promotes. For prostate cancer, the variant contributes to a genetic risk profile that informs PSA screening discussions.

An intriguing pharmacogenomic interaction exists with aspirin: Nan et al.¹⁰¹⁰ Nan et al.
Nan H et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. JNCI, 2013 found that aspirin's colorectal cancer protection was confined to individuals carrying the protective T allele, while those homozygous for the risk G allele derived less benefit. This may relate to the G allele's stronger Wnt activation partially overriding aspirin's anti-Wnt effects.

Interactions

rs6983267 resides in the same cancer risk region as other 8q24 variants that influence different cancer types through distinct mechanisms. Its colorectal cancer association intersects with the mismatch repair pathway: individuals who carry both the rs6983267 GG genotype and variants in mismatch repair genes such as MLH1 (rs1800734) or APC pathway components (rs1801155/APC I1307K) may face compounded colorectal cancer susceptibility. The Wnt pathway activation from rs6983267 combined with impaired DNA repair from mismatch repair variants would create a dual vulnerability — both increased cell proliferation and reduced error correction. This interaction is biologically plausible given that APC mutations and MYC overexpression are sequential events in the adenoma-carcinoma progression model.

The KCNK9 gene encodes TASK3, a two-pore domain background potassium channel¹¹ two-pore domain background potassium channel
K2P channel: always-open K⁺ leak channels that set the resting membrane potential of excitable and secretory cells that is highly expressed in the adrenal zona glomerulosa — the thin outer layer of the adrenal cortex responsible for producing aldosterone. Aldosterone is the steroid hormone that tells the kidneys to retain sodium and water, raising blood volume and therefore blood pressure. When TASK3 channel activity is reduced, zona glomerulosa cells depolarize, increasing calcium influx and stimulating excess aldosterone synthesis. rs6997709 sits approximately 433 kilobases upstream of KCNK9 in an intergenic region that may influence KCNK9 expression through long-range regulatory elements, and its T allele was flagged as a suggestive hypertension signal in the landmark 2007 Wellcome Trust Case Control Consortium (WTCCC) genome-wide association study.

The Mechanism

TASK3 (KCNK9) and its close relative TASK1 (KCNK3) together produce the background K⁺ conductance that sets the resting membrane potential of adrenal glomerulosa cells. Bandulik et al. 2010²² Bandulik et al. 2010
Bandulik S et al. TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation. Horm Metab Res 2010 showed that these channels are molecular targets of angiotensin II signalling: when angiotensin II binds its receptor, it closes these channels, depolarizes the membrane, and opens voltage-gated calcium channels to drive aldosterone secretion. Genetically reducing this channel tone — as in Kcnk9-knockout mice — produces autonomous aldosterone excess and elevated blood pressure even without elevated renin.

rs6997709 is an intergenic regulatory variant; it does not change the TASK3 protein itself. Its position ~433 kb upstream of KCNK9 places it in a region that may harbour enhancer elements with long-range chromatin contacts to the KCNK9 promoter. The T allele may reduce TASK3 expression, tilting the zona glomerulosa toward a more depolarized resting state and enhanced aldosterone responsiveness.

The Evidence

The WTCCC 2007 genome-wide association study³³ WTCCC 2007 genome-wide association study
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007 identified rs6997709 as a suggestive hypertension signal in a British population (n ~2,000 hypertensive cases, ~3,000 controls). A Korean replication study (Hong et al. 2009)⁴⁴ Korean replication study (Hong et al. 2009)
Hong KW et al. Replication of the WTCCC genome-wide association study on essential hypertension in a Korean population. Hypertens Res 2009 found rs6997709 associated with systolic blood pressure in a continuous trait analysis, though it did not reach case-control significance, consistent with a modest additive effect on BP rather than a binary hypertension switch.

Mechanistic support comes from a study by Jung et al. 2012⁵⁵ Jung et al. 2012
Jung J et al. Variations in the potassium channel genes KCNK3 and KCNK9 in relation to blood pressure and aldosterone production. J Clin Endocrinol Metab 2012 that examined 74 KCNK9 SNPs in 795 participants: multiple KCNK9 variants associated with systolic blood pressure in African Americans and with aldosterone production indices in both European and African Americans, placing the KCNK9 locus within the aldosterone pathway that links potassium channel genetics to blood pressure.

A 2025 nutrigenetics scoping review Holzbach et al. 2025⁶⁶ Holzbach et al. 2025
Holzbach LC et al. Nutrigenetics and Nutritional Strategies in Systemic Arterial Hypertension. Nutr Rev 2025 identified rs6997709 among 13 SNPs with documented interactions with dietary sodium intake and blood pressure, consistent with an aldosterone-mediated salt-sensitivity mechanism.

The evidence level is moderate: the original GWAS signal was suggestive rather than genome-wide significant, and the biological mechanism (regulatory effect on KCNK9 expression) has not yet been confirmed by eQTL studies at this specific locus.

Practical Actions

For T-allele carriers, the most relevant lever is dietary sodium. If the KCNK9 locus reduces aldosterone-suppressing channel tone, then high sodium intake may be more pressor for T carriers than for GG individuals. Specifically:

• Restrict dietary sodium to below 2,000 mg/day (roughly 5 g salt), a threshold that clinical guidelines already recommend for hypertension management but that carries extra weight here given the gene-sodium interaction evidence.
• Monitor blood pressure proactively — home blood pressure monitoring provides higher-resolution data than clinic visits and can detect masked or white-coat hypertension.
• Monitor aldosterone-to-renin ratio (ARR) if blood pressure is consistently elevated despite dietary intervention, as the mechanistic model predicts aldosterone-driven low-renin hypertension rather than classical renin-dependent hypertension.

Interactions

The strongest compound interaction partner is GNB3 rs5443, which also showed sodium-interaction in the same scoping review and is a well-established modulator of blood pressure in salt-sensitive populations. ACE rs4646994 and NOS3 rs2070744 interact with the same aldosterone-renin-angiotensin axis; individuals carrying risk variants at multiple loci in this pathway may have additive hypertension susceptibility.

Within the KCNK9 gene itself, rs888345 is the KCNK9 intronic variant most strongly associated with blood pressure in African Americans and with aldosterone production indices in both Europeans and African Americans; it may be in partial linkage disequilibrium with rs6997709 in some populations.